📣 VC round data is live. Check it out!

CryoPort Valuation Multiples

Discover revenue and EBITDA valuation multiples for CryoPort and similar public comparables like Personalis, Eikon Therapeutics, Bide Pharmatech Co, Avacta Group and more.

CryoPort Overview

About CryoPort

CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.


Founded

1990

HQ

United States

Employees

1.2K

Financials (LTM)

Revenue: $183M
EBITDA: ($4M)

EV

$538M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

CryoPort Financials

CryoPort reported last 12-month revenue of $183M and negative EBITDA of ($4M).

In the same LTM period, CryoPort generated $86M in gross profit, ($4M) in EBITDA losses, and had net loss of ($35M).

Revenue (LTM)


CryoPort P&L

In the most recent fiscal year, CryoPort reported revenue of $176M and EBITDA of ($2M).

CryoPort is profitable as of last fiscal year, with gross margin of 47%, EBITDA margin of (1%), and net margin of 44%.

See analyst estimates for CryoPort
LTMLast FY202320242025202620272028
Revenue$183M$176M$233M$228M$176M
Gross Profit$86M$83M$99M$100M$83M
Gross Margin47%47%43%44%47%
EBITDA($4M)($2M)($66M)($79M)($2M)
EBITDA Margin(2%)(1%)(28%)(34%)(1%)
EBIT Margin(21%)(21%)(28%)(29%)(21%)
Net Profit($35M)$78M($100M)($115M)$78M
Net Margin(19%)44%(43%)(50%)44%

Financial data powered by Morningstar, Inc.

CryoPort Stock Performance

CryoPort has current market cap of $667M, and enterprise value of $538M.

Market Cap Evolution


CryoPort's stock price is $13.23.

CryoPort share price increased by 28.9% in the last 30 days, and by 120.1% in the last year.

CryoPort has an EPS (earnings per share) of $1.55.

See more trading valuation data for CryoPort
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$538M$667M-0.1%28.9%57.1%120.1%$1.55

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

CryoPort Valuation Multiples

CryoPort trades at 2.9x EV/Revenue multiple, and (152.8x) EV/EBITDA.

See NTM and 2027E valuation multiples for CryoPort

EV / Revenue (LTM)


CryoPort Financial Valuation Multiples

As of May 15, 2026, CryoPort has market cap of $667M and EV of $538M.

CryoPort has a P/E ratio of (19.0x).

LTMLast FY202320242025202620272028
EV/Revenue2.9x3.1x2.3x2.4x3.1x
EV/EBITDA(152.8x)n/m(8.1x)(6.8x)n/m
EV/EBIT(14.0x)(14.6x)(8.2x)(8.0x)(14.6x)
EV/Gross Profit6.2x6.5x5.4x5.4x6.5x
P/E(19.0x)8.5x(6.7x)(5.8x)8.5x
EV/FCF(27.2x)(25.6x)(11.8x)(14.3x)(19.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified CryoPort Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

CryoPort Margins & Growth Rates

CryoPort grew revenue by 10% but EBITDA decreased by 124% in the last fiscal year.

In the most recent fiscal year, CryoPort reported gross margin of 47%, EBITDA margin of (1%), and net margin of 44%.

See estimated margins and future growth rates for CryoPort

CryoPort Margins

Last FY202420252026202720282029
Gross Margin47%44%47%47%
EBITDA Margin(1%)(34%)(1%)0%
EBIT Margin(21%)(29%)(21%)(19%)
Net Margin44%(50%)44%(19%)
FCF Margin(12%)(16%)(16%)(9%)

CryoPort Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth10%(2%)(23%)10%
Gross Profit Growth10%0%(17%)10%
EBITDA Growth(124%)18%(97%)(124%)
EBIT Growth2%2%(45%)2%
Net Profit Growth(147%)15%(168%)(147%)
FCF Growth(16%)(18%)(25%)(37%)

Data powered by FactSet, Inc. and Morningstar, Inc.

CryoPort Operational KPIs

CryoPort's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

CryoPort's Rule of 40 is 11% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

CryoPort's Rule of X is 26% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for CryoPort
LTMLast FY202320242025202620272028
Rule of 408%11%———
Bessemer Rule of X23%26%———
Revenue per Employee—$0.1M———
Opex per Employee—$0.1M———
R&D Expenses to Revenue9%10%8%8%10%
Opex to Revenue—68%71%73%68%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

CryoPort Competitors

CryoPort competitors include Personalis, Eikon Therapeutics, Bide Pharmatech Co, Avacta Group, Absci, Takara Bio, Pacific Biosciences, SEEGENE, Nautilus Biotechnology and OmniAb.

Most CryoPort public comparables operate across Life Sciences Tools.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Personalis7.3x6.9x(7.1x)(5.8x)
Eikon Therapeutics——(2.1x)(1.9x)
Bide Pharmatech Co3.1x2.9x17.8x—
Avacta Group3638.1x308.5x(23.3x)(17.1x)
Absci264.9x161.6x(7.2x)(6.6x)
Takara Bio2.8x3.2x19.7x—
Pacific Biosciences5.0x4.9x(5.3x)(5.7x)
SEEGENE2.0x2.0x7.7x8.3x

This data is available for Pro users. Sign up to see all CryoPort competitors and their valuation data.

Start Free Trial

CryoPort M&A Activity

CryoPort has acquired 7 companies to date.

Last acquisition by CryoPort was on November 16th 2023. CryoPort acquired Bluebird Express for $10M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by CryoPort

Bluebird Express
Tec4Med
Cell&Co BioServices
F-airGate
Description
Bluebird Express is a logistics provider offering same-day domestic and international shipping from Miami. Established in 2010, it operates a fleet of 50 trucks and partners with DHL for air cargo to Latin America. The firm handles 20,000 parcels weekly, specializing in perishables with temperature-controlled vans.
—
Cell&Co BioServices is a Paris-headquartered biobanking and laboratory services provider. The company manages over 1 million biological samples, including PBMCs and tumor tissues, for clinical trials and research. It operates GLP-compliant facilities in France and offers integrated logistics, processing, and analysis services. Cell&Co serves pharmaceutical giants like Sanofi and academic consortia in Europe. Established in 2012, it expanded to central lab operations supporting Phase III studies.
F-airGate is a Brussels-based courier hub operator at BruCargo airport, providing express parcel sorting and distribution services. With 20 years in logistics, the company connects a global agent network for time-sensitive shipments across Europe, handling pharmaceuticals and e-commerce volumes through its 24/7 facility.
HQ CountryUnited StatesGermanyFranceBelgium
HQ City
New York City, NY
—
Clermont-Ferrand
Brussels
Deal Date16 Nov 20232 Nov 202318 Apr 202218 May 2021
Valuation$10M$3M$7M$5M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all CryoPort acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About CryoPort

When was CryoPort founded?CryoPort was founded in 1990.
Where is CryoPort headquartered?CryoPort is headquartered in United States.
How many employees does CryoPort have?As of today, CryoPort has over 1K employees.
Who is the CEO of CryoPort?CryoPort's CEO is Jerrell W. Shelton.
Is CryoPort publicly listed?Yes, CryoPort is a public company listed on Nasdaq.
What is the stock symbol of CryoPort?CryoPort trades under CYRX ticker.
When did CryoPort go public?CryoPort went public in 1993.
Who are competitors of CryoPort?CryoPort main competitors include Personalis, Eikon Therapeutics, Bide Pharmatech Co, Avacta Group, Absci, Takara Bio, Pacific Biosciences, SEEGENE, Nautilus Biotechnology, OmniAb.
What is the current market cap of CryoPort?CryoPort's current market cap is $667M.
What is the current revenue of CryoPort?CryoPort's last 12 months revenue is $183M.
What is the current revenue growth of CryoPort?CryoPort revenue growth (NTM/LTM) is 10%.
What is the current EV/Revenue multiple of CryoPort?Current revenue multiple of CryoPort is 2.9x.
Is CryoPort profitable?No, CryoPort is not profitable.
What is the current EBITDA of CryoPort?CryoPort has negative EBITDA and is not profitable.
What is CryoPort's EBITDA margin?CryoPort's last 12 months EBITDA margin is (2%).
What is the current EV/EBITDA multiple of CryoPort?Current EBITDA multiple of CryoPort is (152.8x).
What is the current FCF of CryoPort?CryoPort's last 12 months FCF is ($20M).
What is CryoPort's FCF margin?CryoPort's last 12 months FCF margin is (11%).
What is the current EV/FCF multiple of CryoPort?Current FCF multiple of CryoPort is (27.2x).
How many companies CryoPort has acquired to date?As of May 2026, CryoPort has acquired 7 companies.
What was the largest acquisition by CryoPort?$320M acquisition of MVE Biological Solutions on 25th August 2020 was the largest M&A CryoPort has done to date.
What companies CryoPort acquired?CryoPort acquired MVE Biological Solutions, CRYOPDP, Cryogene, Bluebird Express, Cell&Co BioServices, F-airGate, and Tec4Med.
In how many companies CryoPort has invested to date?CryoPort hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to CryoPort

Lists including CryoPort

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial